Professional Experience Tara A. Byrne has experience in all aspects of patent litigation in the pharmaceutical arts. Ms. Byrne has represented leaders in this technological field, including Bristol-Myers Squibb, AstraZeneca, Novartis, Sanofi-Aventis, and Adams Respiratory Therapeutics. Ms. Byrne also has particular experience in litigating ANDA cases brought under Hatch-Waxman. Ms. Byrne is also a licensed Professional Engineer in the State of New York and the State of Vermont. Ms. Byrne is Co-Chair of the firm's Diversity Committee. Professional Activities American Bar Association; New York Intellectual Property Law Association; National Association of Women Lawyers Representative Matters · Bristol-Myers Squibb against BenVenue on patents relating to the cancer drug Taxol®. · AstraZeneca against several generic challengers including Andrx, Genpharm, Dr. Reddy's and Kremers Urban Development Co. relating to AstraZeneca's blockbuster proton-pump inhibitor drug Prilosec®. · AstraZeneca against Ivax on a patent relating to AstraZeneca's calcium channel-blocker drug Plendil®. · AstraZeneca against Andrx, Eon and KV Pharmaceuticals on patents relating to AstraZeneca's beta-blocker drug Toprol®. · Novartis against Breckenridge, Roxane, Taro and Teva on a patent relating to Novartis anti-epileptic drug Trileptal®. · Novartis against multiple generic challengers in an ANDA litigation relating to Novartis' ADHD drugs, Ritalin LA, ®, Focalin®, and Focalin XR®. · Sanofi-Aventis against several generic challengers in an ANDA litigation relating to Sanofi's Eloxatin® product. · Adams Respiratory Therapeutics against Perrigo in an ANDA litigation relating to Adam's drug Mucinex®. Representative Cases Adams Respiratory Therapeutics, Inc et al. v. Perrigo Company et al.
Fed Cir. 2010 Sanofi-Aventis U.S. LLC, Sanofi-Aventis, and Debiopharm S.A. v. Sandoz, Inc. et al.
Fed. Cir. 2009 In re Omeprazole Patent Litigation
S.D.N.Y. 2002 |